1Kantor P, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res, 2000,86:580-588. 被引量：1
2Opie L. The mechanism of myocytes death in ischemia.Eur Heart J ,1993,14(Suppl G) :G31-G33. 被引量：1
3El Banani H, Bernard M, Baetz D, et al. Changes in intracellular sodium and pH during ischemiareperfusion are attenuated by trimetazidine.Comparison between low-and zero-flow ischaemia.Cardiovasc Res , 2000,47 . 688-696. 被引量：1
4Tabbi-Anneni I, Lucien A, Grynberg A. Trimetazidine effect on phospholipids synthesis in ventricular myocyte: consequences in α-adrenergic signalling.Fund Clin Pharmacol, 2003,17: 51-59. 被引量：1
5Di Pasquale P, Lo Verso P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther, 1999,13:423-428. 被引量：1
6Belcher PR, Drake-Holland AJ, Hynd JW, et al.Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc Drus Ther , 1993, 7:149-157. 被引量：1
7Marzilli M. Clinical benefits of a metabolic approach in the management of coronary patients. Rev Port Cardiol, 2000,19 (Suppl 5) :V25-V30. 被引量：1
